Spero Therapeutics Inc (SPRO) Stock Analysis

Spero Therapeutics Inc (SPRO) is a publicly traded company in the HEALTHCARE sector. It trades at $2.83, carries a market capitalization of $163.86M, a price-to-earnings ratio of 10.48. This page summarizes the public market data, fundamentals, and frequently asked questions for SPRO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Spero Therapeutics Inc currently has a Bearish sentiment score of -0.24.

About Spero Therapeutics Inc

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to addressing the pressing challenge of multidrug resistant (MDR) bacterial infections and rare diseases. The company is focused on innovating and advancing novel therapeutics through a robust pipeline, aiming to deliver impactful solutions that improve patient outcomes. With a commitment to combating resistance in bacterial pathogens, Spero is positioned at the forefront of add...

GNG Research Analysis

GNG Research scores Spero Therapeutics Inc (SPRO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SPRO.

Frequently Asked Questions

Does SPRO pay dividends?

Spero Therapeutics Inc (SPRO) does not currently pay a regular dividend.

What is SPRO's P/E ratio?

Spero Therapeutics Inc has a price-to-earnings (P/E) ratio of 10.48.

What is SPRO's market cap?

Spero Therapeutics Inc (SPRO) has a market capitalization of $163.86M with a current stock price of $2.83.